Results 31 to 40 of about 74,225 (263)

Regulatory Effect of miR497-5p–CCNE1 Axis in Triple-Negative Breast Cancer Cells and Its Predictive Value for Early Diagnosis [Retraction]

Cancer Management and Research, 2023
Liu WW, Li WD, Zhang YJ, Zhang ML. Cancer Manag Res. 2021;13:439–447. Following publication of the article, the authors raised concerns over the duplication of the two bar charts in Figure 5D.
Liu WW, Li WD, Zhang YJ, Zhang ML
doaj  

Paracrine Signaling from Breast Cancer Cells Causes Activation of ID4 Expression in Tumor-Associated Macrophages

Cells, 2020
Background: Tumor-associated macrophages (TAMs) constitute a major portion of the leukocyte infiltrate found in breast cancer (BC). BC cells may reprogram TAMs in a pro-angiogenic and immunosuppressive sense.
Sara Donzelli, Andrea Sacconi, Chiara Turco, Enzo Gallo, Elisa Milano, Ilaria Iosue, Giovanni Blandino, Francesco Fazi, Giulia Fontemaggi   +8 more
doaj   +1 more source

ZMIZ2–DUX4–LGR5 Signaling Axis Maintains Stemness Properties and Facilitates Docetaxel Resistance in Triple‐Negative Breast Cancer [PDF]

Advanced science
This study identifies ZMIZ2 as a therapeutic target for docetaxel‐resistant triple‐negative breast cancer, sustaining cancer stemness‐associated properties and docetaxel resistance. ZMIZ2 upregulation enhances DUX4‐mediated LGR5 activation through the SWI/SNF components BRG1 and BAF57.
Gan X, Sun S, Hu R, Feng Y, Wu X, Liu F, Lin X, Zhang X, Rong X, Han Q.   +9 more
europepmc   +2 more sources

MSLN correlates significantly with TNBC status.

, 2014
Abbreviations: MSLN = mesothelin; TNBC = triple negative breast carcinomas. *comparing TNBC with non-TNBC.MSLN correlates significantly with TNBC status.
Gary Tozbikian (674932), Prasad S. Adusumilli (341164), Sujata Patil (674937), Jorge S. Reis-Filho (265332), Britta Weigelt (40755), Alice Y. Ho (674938), Muzaffar Akram (674936), Hannah Yong Wen (674939), Larry Norton (8447), Edi Brogi (674933), Kyuichi Kadota (674934), Jeffrey Catalano (674935)   +11 more
core   +1 more source

Optimization of Short RNA Aptamers for TNBC Cell Targeting [PDF]

, 2022
Triple-negative breast cancer (TNBC) is an aggressive cancer with limited targeted therapies. RNA aptamers, suitably chemically modified, work for therapeutic purposes in the same way as antibodies.
Antonella Zannetti, Luis Exequiel Ibarra, Camorani, Simona, Cerchia, Laura, Roberto Nilo, Fedele, Monica, Monica Fedele, Lisa Agnello, Laura Cerchia, Simona Camorani, D'Argenio, Annachiara, Nilo, Roberto, Agnello, Lisa, Zanetti, Antonella, Ibarra, Luis Exequiel, Annachiara d’Argenio, Zannetti, Antonella   +16 more
core   +1 more source

Decreased 5-Year overall survival in TNBC compared to non-TNBC (n = 314, p = 0.0001).

, 2014
Decreased 5-Year overall survival in TNBC compared to non-TNBC (n = 314, p = 0.0001).
Gary Tozbikian (674932), Prasad S. Adusumilli (341164), Sujata Patil (674937), Jorge S. Reis-Filho (265332), Britta Weigelt (40755), Alice Y. Ho (674938), Muzaffar Akram (674936), Hannah Yong Wen (674939), Larry Norton (8447), Edi Brogi (674933), Kyuichi Kadota (674934), Jeffrey Catalano (674935)   +11 more
core   +1 more source

Revealing Cellular Heterogeneity and Key Regulatory Factors of Triple-Negative Breast Cancer through Single-Cell RNA Sequencing

Frontiers in Bioscience-Landmark
Background: Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer (BC). TNBC has a poor prognosis due to high intratumoral heterogeneity and metastasis, pointing to the need to explore distinct molecular subtypes and gene ...
Hu Zhang, Yanan Sun, Xinna Du
doaj   +1 more source

USP29‐regulated noncanonical stabilization of the hypoxia‐inducible factor‐α in aggressive prostate cancer

Molecular Oncology, EarlyView.
We identify USP29 as the only DUB mirroring CA9 expression, a marker of hypoxia and HIF pathway activation associated with PCA aggressiveness. USP29 stabilizes HIF‐1α and HIF‐2α via a noncanonical mechanism that is independent of PHD/pVHL activity yet relies on proteasomal regulation, establishing USP29 as a previously unrecognized regulator of hypoxic
Amelie S Schober, Leire Moreno‐Cugnon, Laura Martínez‐Pérez, Amaia Ercilla, Amaia Zabala‐Letona, Adrián Vicente‐Barrueco, Maider Fagoaga‐Eugui, Saioa Garcia‐Longarte, Blanca Calle‐Ciborro, Encarnación Pérez‐Andrés, Onintza Carlevaris, Sara Pozo, Isabel Mendizabal, Ugo Mayor, Arkaitz Carracedo, Violaine Sée, Edurne Berra   +16 more
wiley   +1 more source

MSLN expression and clinicopathological characteristics of TNBC.

, 2014
Abbreviations: MSLN = mesothelin; TNBC = triple negative breast carcinoma.MSLN expression and clinicopathological characteristics of TNBC.
Gary Tozbikian (674932), Prasad S. Adusumilli (341164), Sujata Patil (674937), Jorge S. Reis-Filho (265332), Britta Weigelt (40755), Alice Y. Ho (674938), Muzaffar Akram (674936), Hannah Yong Wen (674939), Larry Norton (8447), Edi Brogi (674933), Kyuichi Kadota (674934), Jeffrey Catalano (674935)   +11 more
core   +1 more source

Endorsement of TNBC Biomarkers in Precision Therapy by Nanotechnology

, 2023
Breast cancer is a heterogeneous disease which accounts globally for approximately 1 million new cases annually, wherein more than 200,000 of these cases turn out to be cases of triple-negative breast cancer (TNBC).
Aiswarya Chaudhuri, Rohit Patil, Dinesh Kumar, Deepa Dehari, Sanjay Singh, Ashish Kumar Agrawal, Dulla Naveen Kumar   +6 more
core   +1 more source